Non‐Inferiority of Subcutaneous Efepoetin Alfa Compared to Methoxy Polyethylene Glycol‐Epoetin Beta in Stage 3 or 4 CKD Patients: Insights From a Phase 3 Trial
Open Access
- 14 May 2025
- journal article
- research article
- Published by Wiley in Nephrology
- Vol. 30 (5) , e70046
Abstract
Aim: Efepoetin alfa, a novel long‐acting erythropoietin (EPO)‐hybrid Fc fusion protein, represents a promising erythropoiesis‐stimulating agent (ESA) for addressing anaemia in chronic kidney disease (CKD) patients. This Phase 3 trial was to assess the efficacy and tolerability of subcutaneous efepoetin alfa in comparison to subcutaneous methoxy polyethylene glycol‐epoetin beta in stage 3 or 4 CKD patients.Methods: A randomised, multicentre, open‐label Phase 3 trial enrolled 391 CKD stage 3 or stage 4 patients. Subjects underwent a 20‐week correction period followed by an 8‐week evaluation period. Responders continued treatment for an extra 24‐week extension to evaluate long‐term safety, maintenance effectiveness, and the longer treatment interval.Results: In the efepoetin alfa Q2W (every 2 weeks) group, the response rate was 75.6%; while in the methoxy polyethylene glycol‐epoetin beta Q2W group, the response rate was 69.3%. The difference in the response rate was 6.3% with 95% CI (confidence interval) –3.1% to 15.5%. The lower limit of the 95% CI was above the prespecified non‐inferiority margin of −9.0%. Adverse event rates were comparable between the treatment groups.Conclusion: Efepoetin alfa demonstrated non‐inferiority to methoxy polyethylene glycol‐epoetin beta in correcting anaemia and maintaining haemoglobin (Hb) levels among stage 3 and 4 CKD patients. Moreover, the safety profile of efepoetin alfa was comparable to methoxy polyethylene glycol‐epoetin beta.Keywords
This publication has 28 references indexed in Scilit:
- Natural Form of Noncytolytic Flexible Human Fc as a Long-Acting Carrier of Agonistic Ligand, ErythropoietinPLOS ONE, 2011
- Burden of illness for patients with non-dialysis chronic kidney disease and anemia in the United States: review of the literatureJournal of Medical Economics, 2010
- Healthcare Expenditure and Resource Utilization in Patients with Anaemia and Chronic Kidney Disease: A Retrospective Claims Database AnalysisKidney and Blood Pressure Research, 2009
- Hemoglobin Variability and Mortality in ESRDJournal of the American Society of Nephrology, 2007
- Evidence and implications of haemoglobin cycling in anaemia managementNephrology Dialysis Transplantation, 2007
- Preference for monthly darbepoetin alfa dosing in patients with chronic kidney disease not receiving dialysisCurrent Medical Research and Opinion, 2006
- Kidney function and anemia as risk factors for coronary heart disease and mortality: The Atherosclerosis Risk in Communities (ARIC) StudyAmerican Heart Journal, 2006
- Association of anemia with outcomes in men with moderate and severe chronic kidney diseaseKidney International, 2006
- Hemoglobin cycling in hemodialysis patients treated with recombinant human erythropoietinKidney International, 2005
- RENAL ANAEMIA — THE PATIENT EXPERIENCEEDTNA-ERCA Journal, 2004